Spevatamig Plus Chemotherapy shows 52.4% response rate in pancreatic cancer, more than doubling historical chemotherapy-alone outcomes in Phase 2...

Ublituximab single-infusion dosing achieves bioequivalence target in Phase 3 ENHANCE trial with lower infusion-related reaction rates than prior studies.

Apogee's zumilokibart achieves 65.9% EASI-75 response in Phase 2 atopic dermatitis trial, with fewer injections than current standards.

Zenas BioPharma submits BLA for obexelimab in IgG4-Related Disease, showing 56% flare reduction over 52 weeks with p=0.0005 across...

Guselkumab becomes first IL-23 inhibitor with FDA-approved label for halting structural joint damage in psoriatic arthritis, backed by Phase...

With 51% of Alzheimer's disease-modifying compounds failing Phase III, The Lancet's case for MAMS platform trials in neurology isn't...

At the 2026 Veeva R&D and Quality Summit in Copenhagen, Veeva Systems announced three major AI capabilities: Vault AI,...

Ribo submits RBD1119 Phase 2 application to EMA for coronary artery disease, targeting residual thrombotic risk in stable CAD...

Zanidatamab doubles survival in HER2-positive gastric cancer trial, achieving 29.7 months median OS versus 15.8 months with trastuzumab in...

TG Therapeutics' ublituximab shows bioequivalent exposure in single-dose trial, potentially simplifying MS treatment initiation with reduced clinic visits.